SCHEMBL20522295

SCHEMBL20522295

CC(=O)Nc1nnc(-c2ccc(Br)cc2)s1.Nc1nnc(-c2ccc(Br)cc2)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 4/20 0.60
CSNK2A1 P68400 4/20 0.60
CSNK2B P67870 2/20 0.56
HDAC1 Q13547 1/20 0.53
HDAC2 Q92769 1/20 0.53
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA4 P22748 1/20 0.51
CA5A P35218 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
BLM P54132 1/20 0.51
HPN P05981 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
MGAM O43451 3/20 0.49
GAA P10253 3/20 0.49
SI P14410 3/20 0.49
MGAM2 Q2M2H8 3/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20522351 0.92 CSNK2A2 (0.70) CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2
SCHEMBL474273 0.81 KDM4E (0.66) CSNK2A2CSNK2A1CSNK2BCA1CA2
SCHEMBL4459490 0.78 HDAC1 (0.62) CSNK2A2CSNK2A1HDAC1HDAC2CA1
SCHEMBL10995810 0.77 CA1 (0.58) CSNK2A2CSNK2A1CSNK2BCA1CA2
SCHEMBL9893004 0.76 CSNK2A2 (0.74) CSNK2A2CSNK2A1CSNK2BSMN1; SMN2ALDH1A1
SCHEMBL7930408 0.73 HDAC1 (0.67) CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2
SCHEMBL22712383 0.72 SMN1; SMN2 (0.48) CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2
SCHEMBL11386451 0.72 ALDH1A1 (0.58) CSNK2A2CSNK2A1HDAC1HDAC2BLM
SCHEMBL28352308 0.71 SMN1; SMN2 (0.47) CSNK2A2CSNK2A1CSNK2BHDAC1HDAC2
SCHEMBL22532425 0.71 CSNK2A2 (0.62) CSNK2A2CSNK2A1HDAC1HDAC2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 CN disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
CN-110719910-A Novel inhibitors 前体生物药物股份公司 2020-01-21 CN disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT CSNK2A2 2574/4885CSNK2A1 2963/4885CSNK2B 2363/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS CSNK2A2 2981/4885CSNK2A1 3311/4885CSNK2B 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.